This guide explains what the 7.5 mg dose actually is, why it is not a target maintenance dose, how long people usually stay on it, and what side effects to expect. It draws on the UK Summary of Product Characteristics, the NHS and NICE, and it is careful to flag where strength-specific data simply does not exist.
What the 7.5 mg dose is
Mounjaro 7.5 mg delivers 7.5 mg of tirzepatide per weekly dose from its own pre-filled KwikPen 4. It is one of the six available strengths, sitting between 5 mg and 10 mg 4. In the titration schedule it is the step you reach by increasing 2.5 mg from 5 mg, after at least four weeks at 5 mg 1.
The key thing to understand is its role. The SmPC describes increases being made in 2.5 mg increments after a minimum of four weeks on the current dose, up to a maximum of 15 mg 1. So 7.5 mg is part of the stepwise climb, reached on the way between the lower and higher strengths.
Our Mounjaro dose guide sets out the whole schedule, and this page focuses on what makes 7.5 mg distinctive: its position as a middle step.
At 7.5 mg, as at every strength, the medicine works the same way: tirzepatide is a dual GIP and GLP-1 receptor agonist that reduces hunger, increases fullness and slows stomach emptying 7. The reason for stepping up to 7.5 mg is to increase the strength of that effect when a lower dose has not delivered enough, while keeping the climb gradual enough to stay tolerable 17.
Why 7.5 mg is not a target maintenance dose
This is the central point. The SmPC names the recommended maintenance doses as 5, 10 and 15 mg1. 7.5 mg and 12.5 mg are not on that list. They are intermediate steps that exist so the dose can be raised gradually in 2.5 mg increments, which keeps the titration tolerable 1.
In practice this means 7.5 mg is usually a stage on the way to 10 mg, rather than a level people are aiming to settle on. A prescriber may keep someone at 7.5 mg for a time, for example if 10 mg is not yet tolerated, but the SmPC's framing is that the maintenance targets are 5, 10 and 15 mg 1.
This also explains why there is less strength-specific information available for 7.5 mg, which the next section covers. It is not a flaw in the data; it reflects that 7.5 mg is a transitional step rather than a primary treatment dose.
Side effects at 7.5 mg
Here honesty matters. The pivotal weight management trials studied tirzepatide at 5, 10 and 15 mg, so the SmPC reports side-effect frequencies at those doses, not specifically at 7.5 mg 2. There is therefore no reliable 7.5 mg-specific percentage to quote, and this guide will not invent one.
What can be said is the general pattern. The common side effects across doses are gastrointestinal: nausea, diarrhoea, vomiting, constipation and abdominal pain, mostly mild to moderate, occurring mainly during dose increases and decreasing over time 2. Because 7.5 mg sits between 5 mg (nausea around 24.6 percent in the trials) and 10 mg (around 29.0 percent), it is reasonable to expect a broadly similar experience, but that is interpolation, not a measured figure 2.
One practical point: because 7.5 mg is reached by stepping up from 5 mg, the week of that increase is when side effects are most likely to be noticeable again, as the SmPC notes side effects peak around dose escalation 2. Our article on why side effects sometimes return when you increase the dose covers this.
The serious risks are the same as at any strength and do not change because 7.5 mg is an in-between dose. The SmPC reports acute pancreatitis as an uncommon reaction, asks anyone with persistent, severe abdominal pain to seek immediate medical attention, and cautions about gallbladder problems and dehydration from the gut effects 3. So while 7.5 mg lacks its own trial side-effect figures, the safety cautions that matter most apply to it in full 3.
If side effects at 7.5 mg are difficult, the options are to give the dose a little longer to settle, since the SmPC expects escalation effects to ease over time, or for a prescriber to keep you at a tolerated dose rather than push higher 12. There is no rule that you must reach the next strength on a schedule; the gradual, tolerated climb is the point of the whole approach 1.
Considering treatment for weight management? You can start an assessment with a Cloud Pharmacy clinician, who will review your medical history and confirm whether treatment is appropriate.
How long you stay on 7.5 mg
Because it is an intermediate step, the SmPC's minimum is at least four weeks at the dose before any further increase 1. Many people spend around that length of time at 7.5 mg before moving to 10 mg, if a higher dose is needed and tolerated. Some stay longer if the step up is not yet comfortable.
There is no rule that you must move on from 7.5 mg on a fixed date. The decision to increase, hold or, occasionally, step back down is a clinical one based on how you are responding and tolerating it 1. NICE's six-month checkpoint, looking for at least 5 percent weight loss on the highest tolerated dose, is the broader frame for whether treatment is working 5.
What to expect when you step up to 7.5 mg
Because 7.5 mg is reached by a dose increase, the week of that step is the part most worth preparing for. The SmPC notes that gastrointestinal side effects, mainly nausea, peak around each dose escalation and then decrease over time 2. So a temporary return of nausea or reduced appetite after moving to 7.5 mg is expected rather than a sign something is wrong, and it usually settles within days to a couple of weeks 2.
This is also why the SmPC builds in a minimum of four weeks at the dose before any further increase 1. That window lets the step-up effects settle and lets you and your prescriber see the true effect of 7.5 mg before deciding whether to move to 10 mg. Stepping up too quickly tends to make side effects worse without adding benefit, which is exactly what the gradual schedule is designed to avoid 12.
Practical steps help during the increase: smaller, lower-fat meals, eating slowly, and staying hydrated all tend to ease the gut effects 13. Our article on why side effects sometimes return when you increase the dose covers this pattern in more detail.
What to discuss with your prescriber
If you are at 7.5 mg, useful things to raise are how you are tolerating it, whether your side effects from the last increase have settled, and whether moving to 10 mg or holding at 7.5 mg makes sense for you 1. If you take a sulphonylurea or insulin for diabetes, dose adjustments to those may be needed to reduce the risk of low blood sugar 3.
The interactions that apply at any dose apply at 7.5 mg too. Tirzepatide can reduce the absorption of the contraceptive pill, so a barrier or non-oral method is advised for four weeks at the start and after each dose increase, including this one 8. It can slow the absorption of other oral medicines, and it must not be used in pregnancy 8. Because 7.5 mg is reached by a dose increase, the contraceptive cover point is particularly worth remembering at this step 8.
As with any strength, get Mounjaro only from a registered pharmacy after a clinical assessment 6. Prices can differ between strengths on the private market, but the clinical decision about the right dose should lead, not the cost of a particular pen.
Frequently asked questions
Is 7.5 mg a maintenance dose of Mounjaro?
No. The SmPC lists the recommended maintenance doses as 5, 10 and 15 mg; 7.5 mg (and 12.5 mg) are intermediate titration steps 1. They exist so the dose can be increased gradually in 2.5 mg steps. So 7.5 mg is usually a stage on the way to 10 mg rather than a level you aim to settle on 1.What are the side effects of Mounjaro 7.5 mg?
The trials studied 5, 10 and 15 mg, so there is no reliable 7.5 mg-specific figure 2. The common side effects across doses are gastrointestinal, mainly nausea, mostly mild to moderate and worst around dose increases 2. Since 7.5 mg sits between 5 mg (nausea ~24.6 percent) and 10 mg (~29.0 percent), a broadly similar experience is reasonable to expect, but that is an estimate 2.How long should I stay on 7.5 mg?
At least four weeks before any further increase, per the SmPC, and many people spend around that time at 7.5 mg before moving to 10 mg if needed and tolerated 1. Some stay longer if a higher dose is not yet comfortable. There is no fixed date; it is a clinical decision with your prescriber 1.Why is there a 7.5 mg dose if it is not a maintenance dose?
Because Mounjaro is increased in 2.5 mg steps to keep the titration tolerable, and 7.5 mg is one of those steps between 5 mg and 10 mg 1. Stepping gradually reduces the gastrointestinal side effects that peak around each increase 2. It is a transitional strength rather than a primary treatment dose.Can I stay on 7.5 mg long term?
The SmPC's recommended maintenance doses are 5, 10 and 15 mg, so 7.5 mg is not framed as a long-term target 1. In practice a prescriber may keep you at 7.5 mg for a time, for example if 10 mg is not yet tolerated, but the usual path is either down to the 5 mg maintenance dose or up to 10 mg 1. It is a clinical decision based on how you respond and tolerate it 1.Does Mounjaro affect contraception at 7.5 mg?
Yes, and the dose-increase point is especially relevant here. Tirzepatide can reduce the absorption of the contraceptive pill, so the SmPC advises a barrier or non-oral method for four weeks at the start and for four weeks after each dose increase, including the step up to 7.5 mg 8. It can also slow absorption of other oral medicines, so tell your prescriber and pharmacist what you take 8.Your next step
Mounjaro 7.5 mg is best understood as a middle step, not a finish line: the recommended maintenance doses are 5, 10 and 15 mg, and 7.5 mg is the rung between two of them. There is no strength-specific trial side-effect figure for it, but the usual gut effects apply, strongest around the increase.
If you are at 7.5 mg, talk to your prescriber about how the last step up has settled and whether moving to 10 mg or holding makes sense for you. Only obtain Mounjaro from a registered pharmacy, and report side effects through the Yellow Card scheme.
Disclaimer
This guide is for general information only and does not constitute medical advice, diagnosis or treatment. The information here describes general clinical context based on UK regulatory sources cited above; it is not a recommendation for any specific medicine or treatment, which can only be made by a prescriber following individual assessment.
If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.
If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.
